
Katharine A Collier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7413285/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Salvage nivolumab and ipilimumab after prior antiâ€PD â€1/ PDâ€L1 therapy in metastatic renal cell carcinoma: A metaâ€analysis. Cancer Medicine, 2022, , .	2.8	5
2	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Medicine, 2022, 11, 3106-3114.	2.8	10
3	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	3.0	11
4	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611.	2.3	16
5	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 2021, 7, 603.	7.1	37
6	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Medicine, 2021, 13, 89.	8.2	10
7	Early phase clinical studies of <scp>AR</scp> â€42, a histone deacetylase inhibitor, for neurofibromatosis type 2â€associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology, 2021, 6, 1008-1019.	1.5	14
8	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 1815.	7.1	40
9	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2021, 5, 1777-1787.	3.0	5
10	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer, 2021, 7, 142.	5.2	13
11	Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions. ICO Precision Oncology, 2019, 3, 1-11.	3.0	8